Retinal cell map could advance precise therapies for blinding diseases
May 14, 2022
A discovery by investigators at the National Eye Institute sheds light on tissue targeted by age-related macular degeneration and other diseases.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Retina
Stealth BioTherapeutics announces data from Phase 2 study of geographic atrophy candidate
May 23, 2022
According to the company, the ReCLAIM-2 study of elamipretide demonstrates a correlation between ellipsoid zone dysfunction and vision.
VLRC Eye Van making 50th anniversary tour
May 14, 2022
The Eye Van, operated by Vision Loss Rehabilitation Canada, is a mobile medical clinic that delivers eye care in northern Ontario communities where ophthalmology services aren't readily available.
Phase 3 PEACHTREE, AZALEA integrated study results presented at ARVO 2022: BCVA gains, CST reduction with Xipere
May 12, 2022
The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.
Cell therapy trial shows promising results for patients with advanced dry AMD
May 10, 2022
The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).
New PRO instrument helps measure patient experience with therapies such as anti-VEGF agents, lasers to treat their eye disease
May 09, 2022
Diana Do, MD, professor of ophthalmology at Stanford's Byers Eye Institute, presents research on a newly developed, novel patient-reported outcome instrument (PRO) for patients who have proliferative diabetic retinopathy and who are undergoing treatment with either intravitreal anti-VEGF therapy, or panretinal photocoagulation.
Unraveling genes, mutations in inherited retinal diseases
May 05, 2022
Variable TULP1 missense mutations in inherited retinal diseases.
Pilot study examines spectacle lenses to control myopia
May 03, 2022
In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Eva Chamorro, PhD, MSc, points out that myopia control spectacle lenses affect the diurnal rhythms in the AL in young adult human and produced a small short-term increase in the AL that varies in intensity and time interval for each of the 3 studied lenses.
THR-687 protective against diabetic macular edema hallmarks in diabetic rats
May 03, 2022
THR-687 is currently being evaluated in a phase 2 clinical trial in patients with DME. The first data from the dose-optimization study is expected to be released in the first half of 2022.
Investigators outline relationship between dry eye disease and high myopia in teenagers
May 02, 2022
In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Osama Ibrahim Hirayama, MD, and colleagues offered results that demonstrating that anisometropia and astigmatic error were greater among the patients with high myopia compared with the other groups. Compared with the subjects with no myopia, those with high myopia reported significantly more dryness, less photophobia, and less pain.
Latest News
Understanding the biological causes and cell types that lead to one of the leading causes of irreversible blindness worldwide could benefit treatment in patients
Aerie Pharmaceuticals doses first participant in COMET-2 study of dry eye candidate
Technology, people key to improving health outcomes, driving revenue